177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme
Arunav Kumar, Sanjana Ballal, Madhav Prasad Yadav, S.T. ArunRaj, K.P. Haresh, Subhash Gupta, Nishikant Avinash Damle, Ajay Garg, Madhavi Tripathi, Chandrasekhar Bal
Source record
Source: Crossref
Published: Dec 1, 2020
DOI: 10.1097/rlu.0000000000003142
Open original source ↗Source abstract
Abstract A 37-year-old man, treated case of left temporal glioblastoma presented with headache, seizures, and progressive right-sided weakness with MRI evidence of recurrence. Exploratory 68 Ga-PSMA PET/CT demonstrated PSMA expression in the recurrent lesion; it was decided to treat this patient with 177 Lu-PSMA-617. After 3 cycles of 177 Lu-PSMA-617, 68 Ga-PSMA PET/CT showed significant reduction in PSMA uptake and regression in size of lesion on MRI with improvement in patient’s symptoms and performance status. 177 Lu-/ 68 Ga-PSMA theranostics has potential in patients with recurrent glioblastoma multiforme when other therapeutic options are not feasible.
Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.